| Flynn, Kathryn E |
Medical College Of Wisconsin
United States |
Symptom Monitoring using Patient-Reported Outcomes to Optimize Medication Use (SyMPTOM) |
1R01CA285925-01A1 |
|
Ellen Richmond, M.S., GNP-BC |
| Forsberg, Flemming |
Thomas Jefferson University
United States |
Prostate Cancer Diagnosis by Multiparametric Ultrasound |
5R01CA252311-05 |
|
Richard Mazurchuk, Ph.D. |
| Frazier, Anne Lindsay |
Dana-Farber Cancer Inst
United States |
Assay Validation of a Circulating miRNA Test for Diagnosis and Monitoring of Malignant Germ Cell Tumors |
5UH3CA240688-05 |
|
|
| Freedland, Stephen Jay |
Cedars-Sinai Medical Center
United States |
A Comparative Study of Risk Factors for Men with and without Prostate Cancer at the VA Medical Center in Durham |
3R01CA280081-02S1 |
|
Young Kim, Ph.D. |
| Friday, Bret E.B. |
Essentia Institute Of Rural Health
United States |
Essentia Health Community Cancer Research Program - NCORP |
5UG1CA189812-11 |
|
Vanessa A. White, M.P.H. |
| Furuta, Saori |
Case Western Reserve University
United States |
Normalizing arginine metabolism with sepiaptein for immunostimulatory-shift ofHER2+ breast cancer |
5R01CA248304-05 |
|
Winfred Malone, Ph.D., M.P.H. |
| Fuschiotti, Patrizia |
University Of Pittsburgh At Pittsburgh
United States |
Develop IL13Ra1 for diagnosis of early-stage mycosis fungoides |
1R21CA280445-01A1 |
|
Wendy Wang, Ph.D., M.Sc. |
| Garcia, Jose M. |
Seattle Inst For Biomedical/Clinical Res
United States |
SArcopenia in Men with Prostate Cancer undergoing ADT (SAP-ADT) |
1R01CA279220-01A1 |
|
Marge Good, RN, M.P.H., OCN |
| Geisler, Stefanie |
Washington University
United States |
Developing mechanism-based strategies to treat chemotherapy-induced peripheral neuropathy |
5R37CA267905-03 |
PAR-19-325 (R01 Clinical Trial Optional) |
Asad Umar, D.V.M., Ph.D. |
| Germain, Doris A |
Icahn School Of Medicine At Mount Sinai
United States |
Exploring ovarian-derived hormone STC1 as the mediator of the protective effect of breast feeding against breast cancer. |
5R21CA270702-02 |
PAR-20-292 (R21 Clinical Trial Optional) |
Marjorie Perloff, M.D. |